BGB 290

Drug Profile

BGB 290

Alternative Names: BeiGene-290; BGB-290; PARPi - BeiGene

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioblastoma; Solid tumours

Most Recent Events

  • 08 Sep 2017 Preliminary efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 09 Aug 2017 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Newly diagnosed, First-line therapy) in USA (PO) (NCT03150862)
  • 09 Aug 2017 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03150862)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top